<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811421</url>
  </required_header>
  <id_info>
    <org_study_id>IP.07.31080.002</org_study_id>
    <nct_id>NCT00811421</nct_id>
  </id_info>
  <brief_title>Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy</brief_title>
  <acronym>MiPPAD</acronym>
  <official_title>Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barcelona Centre for International Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, University of Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université d'Abomey-Calavi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Schweitzer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ifakara Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Investigacao em Saude de Manhica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vienna School of Clinical Research (VSCR), Austria.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malaria in Pregnancy Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at comparing the safety, tolerability and efficacy of Mefloquine (MQ) to
      Sulfadoxine-Pyrimethamine (SP) as Interment Preventive Treatment in pregnancy (IPTp) for the
      prevention of malaria effects on the mother and her infant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current recommendation by the World Health Organization (WHO) to prevent malaria
      infection in pregnancy in areas of stable malaria transmission relies on:

        -  Prompt and effective case management of malaria illness

        -  The use of intermittent preventive treatment (IPTp) with at least 2 treatment doses of
           sulfadoxine-pyrimethamine (SP) and

        -  The use of insecticide treated nets (ITNs)

      However, the spread of parasite resistance to SP, particularly in eastern Africa, and the
      significant overlap in some regions of malaria transmission and high prevalence of HIV
      infection, have raised concerns about the medium and long-term use of SP for IPTp.

      HIV infection increases susceptibility to malaria and may reduce the efficacy of
      interventions. The evaluation of alternative antimalarials for IPTp is thus urgently needed
      also involving HIV infected women.

      Of all the current available alternative antimalarial drugs, mefloquine (MQ) is the one that
      offers the most comparative advantages to SP.

      A randomized multicenter trial will be conducted in 4 sites in Africa (Benin, Gabon, Tanzania
      and Mozambique) in order to compare the safety and efficacy of SP versus MQ as IPTp in the
      context of ITNs. In addition, MQ tolerability will be also evaluated by comparing the
      administration of MQ as a single intake with its administration as split dose in two days. In
      total 4716 pregnant women will be enrolled at the antenatal clinic (ANC) and will be followed
      until the infant is one year old.

      Besides, in those countries where HIV prevalence in pregnant women is &gt; 10%, MQ-IPTp will be
      compared to Placebo-IPTp in HIV infected pregnant women receiving cotrimoxazole (CTX)
      prophylaxis. This trial will be double blinded and will be carried out in Kenya, Tanzania and
      Mozambique. It will involve 1070 pregnant women that will be followed until the infant is 2
      months old.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trial 1 (IPTp MQ vs IPTp SP): Low birth weight.</measure>
    <time_frame>day 0, birth</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trial 2 (CTX+IPTp MQ vs. CTX+IPTp placebo): Peripheral parasitaemia.</measure>
    <time_frame>day 0, delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trial 1: Prevalence of placental P. falciparum infection. Prevalence of moderate maternal anaemia at delivery.</measure>
    <time_frame>day 0, delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trial 2: Prevalence of placental P. falciparum infection. Prevalence of low birth weight babies (&lt; 2500 g).</measure>
    <time_frame>day 0, birth</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">5820</enrollment>
  <condition>Pregnancy</condition>
  <condition>Malaria</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Trial 1: IPTp-SP+LLITNs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIV-negative pregnant women receiving 2 doses of IPTp (500mg of sulfadoxine and 25 mg of pyrimethamine) in the context of long lasting Insecticide Treated Nets (LLITNs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trial 1: IPTp-MQ (full dose) + LLITNs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-negative pregnant women receiving 2 full doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trial 1: IPTp-MQ (split dose)+LLITNs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-negative pregnant women receiving 2 doses of MQ as IPTp split dose over 2 days (15mg/kg) in the context of long lasting Insecticide Treated Nets (LLITNs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trial 2: CTX+IPTp-Placebo+LLITNs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-positive pregnant women receiving 3 doses of IPTp (placebo) in the context of long lasting Insecticide Treated Nets (LLITNs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trial 2: CTX + IPTp-MQ+ LLITNs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-positive pregnant women receiving 3 doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulphadoxine-pyrimethamine</intervention_name>
    <description>SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit</description>
    <arm_group_label>Trial 1: IPTp-SP+LLITNs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefloquine (full dose)</intervention_name>
    <description>MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp</description>
    <arm_group_label>Trial 1: IPTp-MQ (full dose) + LLITNs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefloquine (split dose)</intervention_name>
    <description>MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp</description>
    <arm_group_label>Trial 1: IPTp-MQ (split dose)+LLITNs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp</description>
    <arm_group_label>Trial 2: CTX+IPTp-Placebo+LLITNs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mefloquine</intervention_name>
    <description>MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp</description>
    <arm_group_label>Trial 2: CTX + IPTp-MQ+ LLITNs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Trial 1:

          -  Permanent resident in the area

          -  Gestational age at the first antenatal visit ≤ 28 weeks

          -  Signed informed consent

          -  Agreement to deliver in the study site's maternity(ies) wards

        Trial 2:

          -  Permanent resident in the area.

          -  Gestational age at the first antenatal visit ≤ 28 weeks

          -  HIV seropositive (after voluntary counseling and testing)

          -  Indication to receive CTX prophylaxis (according to the national guidelines)

          -  Signed informed consent

          -  Agreement to deliver in the study site's maternity(ies) wards.

        Exclusion Criteria:

        Trial 1:

          -  Residence outside the study area or planning to move out in the following 18 months
             from enrollment

          -  Gestational age at the first antenatal visit &gt; 28 weeks of pregnancy

          -  Known history of allergy to sulfa drugs or mefloquine

          -  Known history of severe renal, hepatic, psychiatric or neurological disease

          -  MQ or halofantrine treatment in the preceding 4 weeks

          -  HIV infection

          -  Participating in other studies

        Trial 2:

          -  Residence outside the study area or planning to move out in the following 10 months
             from enrollment

          -  Gestational age at the first antenatal visit &gt; 28 weeks of pregnancy

          -  Known history of allergy to CTX or MQ

          -  Known history of severe renal, hepatic, psychiatric or neurological disease

          -  MQ or halofantrine treatment in the preceding 4 weeks
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara Menendez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barcelona Centre for International Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculté des Sciences de la Santé (FSS), Université d'Abomey Calavi</name>
      <address>
        <city>Allada</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Rsearch Unit (MRU), Albert Schweitzer Hospital</name>
      <address>
        <city>Lambaréné</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenya Medical Research Institute (KEMRI)/ CDC</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaçao em Saúde da Manhiça (CISM)</name>
      <address>
        <city>Manhiça</city>
        <state>Maputo</state>
        <country>Mozambique</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ifakara Health Institute (IHI)</name>
      <address>
        <city>Dodoma</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>Gabon</country>
    <country>Kenya</country>
    <country>Mozambique</country>
    <country>Tanzania</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2014</last_update_posted>
  <responsible_party>
    <name_title>Professor Clara Menendez Santos</name_title>
    <organization>Barcelona Centre for International Health Research (CRESIB), Spain</organization>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>HIV</keyword>
  <keyword>Prevention</keyword>
  <keyword>Malaria prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
    <mesh_term>Mefloquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

